Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a clinical-stage biotech company focused on psychedelic-inspired medicines and digital therapeutics for neuropsychiatric disorders. Its lead candidate, MM-120 (LSD derivative), targets generalized anxiety disorder and ADHD, with additional programs in 5-HT2A modulation. MindMed integrates pharmacology with digital biomarkers to personalize treatment outcomes. It provides investors with speculative exposure to the evolving landscape of mental health therapeutics and psychedelic drug development.
Τελευταία άρθρα για μετοχές